>> mel, have a great vacation. >> i'm off on vacation. i'll see new a week or so. stay tuned. more my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere. my job is to help you find it. "mad money" starts now. hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. i'm just trying to make you money. my job isn't just to entertain but to educate and teach you. call me at 1-800-743-cnbc. or tweet me @jimcramer. suddenly, out of nowhere, we checked a half dozen boxes, at least momentarily, and people are feeling better about the big issues that have kept this market down for so long.

remember this checklist i laid out earlier this week? and what can only be described as a pretty amazing 24 hours, these worries were addressed, not solved. even though piece positives could be quickly undown, dowun a terrific rally, even as we gave up some of the gains at the close. we had gotten so oversold, many people had been relentlessly selling for days. money managers have become so viscerally negative, it wouldn't take much to spur a rally. think about it, almost every stock in the s&p 500 has been trashed for ages, except a narrow group of winners in 2015, the much-anointed acronymic f.a.n.g. -- facebook, amazon, netflix, and google -- yesterday these stocks were obliterated. they were gasping for air.

the bear had sunk its teeth into their collective jugular. it was like sweet honey for the grizzly. as bruce springsteen taught us, you can't start a fire without a spark. when we left the office last night, i know we sure didn't have one. you know what i wanted to do? it was like the old days. i wanted to sip a bottle of cheap scotch on my dirty linoleum floor. when that closing bell rang, believe me, i would have. but the wife has me on this darn cleanse that would suck the life out of anyone, stuff with quinoa. i wonder, my spinach smoothie that now passes for dinner at the cramer household. anyway. before i settled into especially side five of "narcos," china was getting trashed as usual, and the now voting federal reserve

member from st. louis was giving a speech on fed policy this morning. could there be a worse setup? my only solace, it had been years since we have been as deep as minus 8 on the s&p capital oscillator, something i follow and swear by. the s&p, folks, thank you very much, tell me you have to go all the way back to august of 2001, a pretty fabulous buying option, but you see another reading that negative like the one we had last night. you made a real killing if you bought back then. for all that negativity, one by one things started falling into place for at least the session. first we got something positive that my colleague sara eisen pointed out this morning on her fabulous show. a front page article in the "new york times" fairly prominently placed, headlined, "u.s. stocks continue slide on fears of slowdown." wow, a one-two punch. first you need the decline to be part of the american

consciousness, everyone has to know how bad it is out there before you can expect any legitimate bounce, let alone a bottom. second, finally the fed will feel defensiveness about its new-found hawkishness. nobody wants to be blamed as the cause of the next recession, including janet yellen and company. next, i was glad to see that china for once wouldn't stand in our way. no new economic news from the world's most populous country. there was one hopeful sign. the stock market there opened down, then finished up. now, i'm sure that's just the communist party propping up things all over again, no long term solution there. short term, though, it does seem like the government's buy program has its mojo back. traders know that a market that opens low and finishes up dramatically is a market we might actually want to participate in, even if it's phony. at the very least we know the chinese economists can manipulate the market up again, which is actually a positive.

third, oil actually, as we say, caught a bit. for two days oil flirted with breaking through the $30 barrier, something we all know is going to cause a tremendous number of failures in the industry. today, by putting some distance from $29, there can be hope that things can get better in the oil patch, after two weeks of declines. fourth, we're now getting into the meat of earnings season. and how best to get it rolling than with a fantastic no-fly zone quarter from large bank j.p. morgan, delivering a remarkable number. good trading results, no losses or charges of any import, and dramatically reduced risk profile via smaller balance sheet. what's not to like? i cheered when i saw the release. so did the market. it looks like no one heard the sirens blaring from best buy, which reported a miserable holiday quarter. this won't be the case tomorrow as we've already got a disappointing forecast from

intel and a shortfall from analog devices because of weak mobile phone chip orders, ouch. finally, if what can only be described as a genuine miracle, the st. louis fed hawk gave a thoughtful presentation where he questioned whether inflation might be much less worrisome than he thought, going into the december rate hike meeting, because oil had broken down so convincingly. his talk make you realize the fed isn't just staying there saying all that matters is employment, and since that's strong, we should keep tightening. it made you realize the fed is acutely conscious of another input, the decline of oil, and how it makes the possibility of inflation roaring back much less likely, therefore the fed doesn't have to be heavy handed with rate hikes. second, it made it clear that the big increase in consumer consumption came to an end in 2015. finally, in a veiled way, it told you that lower oil, rather than producing a series of

blessings, seems to have having a negative impact on prices across the board. wow. that's about as close as we're he ever going to get to hearing a hawkish fed board member say, wait a second, let's hold off on more hikes, at least until we see some signs of inflation rather than deflation. remember what i said, you don't need all the boxes checked. but when the fed board member who is perceived to be the biggest champion of lockstep rate hikes starts to notice that inflation expectations are vastly reduced, you can pretty much take all that chatter about the urgent need for four rate hikes off the table. you couple that with slowdown fears, and the flash crash lows, another box i wanted to see check before the index ignited sky ward. that's the most bullish script possible.

when you put all these positives together, f.a.n.g. -- facebook, amazon, netflix, and google -- being taken out and shot, the selloff making the front page of the "new york times," the most negative oscillator readings since 2011, a nice rebound from the lows in china, a prominent rally in the price of oil, and a successful retest of the august 24th lows, not to mention the most prominent fed hawk blinked, you have the spark that created the flame that engulfed this market, and perhaps for a few days sending the bear back to her dirty linoleum den. i would use it to get out of the stocks at better prices than you ever could expect, just 24 short hours ago. i'm going to sam in texas. sam. >> caller: jim, big booyah to ya, dallas, texas. >> holy cow. say hello to mark cuban.

what's going on? >> caller: jcp, i've been off and on the last several years, i made a little money. is this ever going to go back to its glory days? >> i think it's seven bucks, maybe catch a buck trade. you could make a buck. phil in massachusetts. fill. >> caller: hi, mr. cramer. this is phil from massachusetts. >> how are you? >> caller: good. it's an honor to speak to you. >> thank you, phil. >> caller: my question is concerning walgreen's. is it a buy, sell, or hold? >> my travel trust has a huge position in walgreen's. the stock did not go up initially today because they thought they were going to buy webmd. when that was dispelled, walgreen's took off. it's a huge buy here. the quarter was fabulous. dennis in michigan. dennis. >> caller: yes, hi, jim. jetblue, like the other airline stocks, are down over the last

several months. jetblue over 16%. yet the oil prices have been down significantly. the air lines should be thriving in particular with the capacity in the bookings. what is up? >> a lot of people feel that the airlines, there's finally been some price competition out there, that's worrisome to people. that's why people feel the earnings estimates are not going to be made. i might talk more about that later in the show. rick in illinois. rick. >> caller: yeah, the 2014 budget bill contains an amendment to prevent the department of state to prosecute states for selling medical marijuana. do you think gw pharma is a spec stock? >> most certainly. this is company that has legal marijuana from overseas. but the studies have been mixed of late and no one's really championing the idea of having

this kind of -- what would be a staple form of marijuana. the stock is not working right now, but no speculative stocks are. it's all about which boxes are trying to be checked. some big issues were addressed over the last 24 hours, addressed, not fixed, okay? at least for now. on "mad money" tonight, think you've found a bargain in this market? not so fast, it could be a value trap. i'll explain. when all hell was breaking loose in the averages, did you just stand there or did you do something? i'll tell you why you should pull yourself up by the bootstraps. and one biotech company that solves your headache. i'll reveal that ahead. stick with cramer. >> announcer: don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer, #madtweets. send jim an e-mail to madmoney@cnbc.com or give us a call at 1-800-743-cnbc.

miss something? head to madmoney.cnbc.com.

after a rare day like we just had, you know, what it's my job to do? i'll stop you from letting certain stocks become dangerous. tonight i want to warn you about the pearls of what's known as value traps. i see a ton of them out there in this environment. what exactly is a value trap? it's a stock that initially appears inexpensive but it eventually turns out the only reason the multiple looked low was because the earnings estimates it was based on were too darned high. and when the numbers start coming down, the estimates start coming down, the stock is obj t oblitera obliterated. this can be a difficult concept for people because it's supposed to help you determine benchmarks. it's a great tool that allows

you to figure out what the market is willing to pay. it gives you a way to make apples to apples comparison between different companies in the same industries. typically we view that stock as inexpensive and assume it can't possibly have more downside. we've seen stocks with incredibly low pe multiples languish or get blown out. these are the value traps i'm talking about. they can fool you if you don't know had a to watch out for. in what cases should we view a low pe multiple with suspicion? this method of valuing stock has two components. we're always focusing on fluctuations in what's known as the multiple or m of what we'll pay for the earnings. but the other part of the equation, the earnings themselves or the e, can fluctuate too. if these earnings estimates are too high, then a super low multiple can be a huge red flag, because it's signaling that the

numbers will need to be cut. and rising or falling earnings estimates are still the number one driver of higher or lower stock prices. let me give you some hard core examples so you understand how these value traps look in the wild. first, how about a stock with one of the lowest multiples in the s&p 500. i'm talking about ensco. it's fooled so many people. right now it has an $11 stock allegedly trading as low as 4.9 lower than wall street's estimate of $2.27 per share. that's the average of all the estimates put out there by the analyst community. in a vacuum that number seems extraordinary, what a bargain, especially at a time when the average stock in the s&p is selling 16 times earnings. given that their stock is down why the% ov 80% in the last two years, wow, i want that one. i think you would be dead wrong.

the problem, it only looks low right now because the earnings estimates are still too high. the fact is the company's core offshore drilling business is eroding right before our eyes, as high cost offshore oil production is simply not economical with crude here at $31 a barrel. the day rates for these offshore rigs of ensco have plummeted. this whole industry will continue to be in a house of pain. and many of the smaller companies may not even survive in their present form. in that case, ensco is likely going to have to slash those earnings forecasts again. and worse, they may need to cut the dividend again, even though they already slashed your payout last year from $3 a share to 60 cents a share. in short their low multiple may

seem enticing. to quote everyone's favorite line from "star wars," it's a trap. >> it's a strap! >> that low multiple is signaling investors don't trust that ensco will even be able to come close to meeting earnings estimates, which is what makes the stock a value trap. once you learn faith in the earnings, the pe multiple is meaning littles meaningless. they've been a value trap for years now. it appeared to be selling for eight times earnings, but of course the company has consistently missed those numbers by a mile. hence the stock's vicious 80% decline over the last couple of years. i think it could still go lower. when it was in the 50s, i had it for my travel trust. i thought it looked so cheap. fortunately i got out before too big a loss. it was a loss. next up, it's possible to be fooled by a company's overall optimistic long term forecast. consider ibm.

back in 2012, their old ceo projected $20 per share by 2013. three-year projection. the stock surged up to $215 in 2015. of course ibm's business has been in free fall for ages. they had to slash that forecast down to $15 and now it's looking like even that number may not be attainable. the stock turned out to be very expensive, particularly those who have watched the $70 slide in the stock. here's one that might seem counterintuitive. the airlines. united continental is trading at 5.5 times earnings. you would think these stocks would be bargains, especially since jet fuel is in free fall. but it may not be the case. why don't people believe that united and american can make those numbers? right now the airlines are

caught in many different markets with a vicious price war, reminiscent of how this industry used to be for decades before the new-found era of good feelings a few years ago. after unfortunate terrorism fears, a global economic slowdown, and it's easy to see how the real earnings may be a lot lower than the estimates, which means the stocks could have a downside, although i'm more inclined to be positive on southwest and delta. scx has an ultralow pe multiple, plummeting from $60 in 2010 down to $4 as of today. of course that low multiple made investments think they were unattainable, and they were right with the commodity collapse. analysts thought u.s. steel investors could hearn $3.70 a

share. instead they lost $3.49 in the first three months of 2015. turns out the multiple should have been a negative number. if today's bouyant stock makes you want to pick a stock with a low price to earnings multiple, just remember not all of them are cheap. ensco, ibm, freeport, you might just be looking at a value trap. that's why you have to rethink your notion of what's keeping. because something that seems cheap now could very well turn out to be very expensive and costly to you later on. much more "mad money" ahead. biotech has been one of the worst performing sectors in 2016. could one company's rise today be a turning point? then it seems like a fight or flight moment f the averages. what's your choice? why it may be time to buy on the next dip. and stocks may be off to the worst ever start since the new

year. that doesn't mean you can't protect your profits. i'll make sure you do. stick with cramer!

complacency is not a disease that only afflicts bull markets. it can also be too complacently

negative out there. you can be too comfortable in your belief that everything will keep going lower no matter what. it's the other side of the coin. yesterday traders dismissed it as one more day of horrible action. but the ones who sense that stocks are getting too cheap, they can change their view. they look like real winners. last night i said my travel trust did some buying in the last hour of trading because it was so ugly and miserable you had to pull the trigger. and we did some buying on a few stocks where we had set price levels long before the heat of the action. so when those levels were reached, we had no choice but to do some buying for the charitable trust. that's called basic discipline. we couldn't just abandon it and say, it's really scary out there, we've got to change what

we said we were going to do when these stocks were higher. no. we went in, methodically and coolly, and picked the stocks. believe me, i sure didn't want to. i mean, it was painful to pull that trigger. and i really didn't want to come out here tonight and admit that the trust had bought stock and then seen the market drop another 2 or 3% which i think was the perceived wisdom when we left last night. oh, i wanted to waffle. then i got a reminder that you can't freeze up and stay negative when stocks start hitting levels where you figured they would be buyable based on homework done during a less emotionally charged moment. i had said if we got back to certain levels, you have to do some buying. i heard from someone i regard as a tremendous trader yesterday afternoon who didn't have a ton of cash and heeded the market for a very long time. she had been waiting and waiting for f.a.n.g. to glow up. f.a.n.g. -- facebook, amazon, netflix, and google -- and for

everyone else to join her in hitting the market. finally she sensed her moment had come. i had to agree. if not now, she said, then when? if you don't buy something when the market is universally and deservedly despised, then when will you buy? especially if you're sitting on a boatload of cash. everyone had joined her in the negative column. remember, it's not like a bell goes off and says, this is your chance to buy, because the coast is gloriously clear. in fact, it's the opposite. you need to have the discipline to buy when everyone hates the market. the same discipline that makes you sell when everybody loves it. yes, you can be too complacently negative at the bottom just like you can be too complacently positive at the top. i have no idea if the move we saw today is the legitimate bottom or just one more heartbreaking bounce. i do like the fact that some of the boxes that needed to be checked to form a bottom have at least been half heartedly, let's

say, addressed. remember, when a market gets th this oversold, it doesn't take more than an errant spark to spark a forest fire of buying. more important, you always have to put yourself in the other guy's shoes. just as there are hedge fund managers that are bleeding from their eyeballs and mutual fund managers getting massive redemptions, there are also plenty of people like the person who called me yesterday, people who haven't bought in years, in this case the last time i heard from her about stocks was in november of 2011, arguably the last great buying opportunity. people who have waited patiently for the right moment when even the most beloved of stocks is at last turned on. today was a textbook example of the importance of discipline. nobody wanted to buy stocks why he wanted yesterday. it felt like the world was ending. but you can't let emotions influence your decision-making

process. your native conviction would have had you selling everything yesterday before today's rebound. patrick in arizona. >> caller: hello, jim. which energy stocks in your opinion may not survive like lid or freeport that we seniors and retirees may want to dump now regardless of our losses? >> jeez, i've been working with carlton english at realmoney.com to put together this list of the companies we're worried about. the problem is the vast majority that i'm worried about do not fit our market cap disciplines. and are a dollar or $2 or $3. if you have an oil stock down below 10 and has a lot of debt, you should be worried, let's put it that way. that really is the parameters that when i eyeball, they all seem to have that agglomeration of statistics, so to speak.

nick in florida. >> caller: booyah, jim. thank you for everything you do. i watch your show every day, it's the best show on tv. >> wow, thank you very much. i love that. >> caller: yelp, i'm wondering what the possibilities are for it to be acquired by google. >> i think the time has come and gone for that. companies don't want to buy a company that's not doing well. remember, the takeovers tended to occur for companies that are doing well whose stock does not reflect the goodness, as opposed to companies that are not doing well and down on their luck. that doesn't attract a takeover bid. florence. >> caller: hi, jim, i'm so pleased to talk to you but mostly to ask the recommendations for yahoo!. i know for many days the leadership of marissa meyer was

in question, and also whether alibaba is the strong suit she hold. is that enough to move the needle? you're my tutor for tonight. >> florence, thank you for the confidence you've placed in me. i hope i can return it with good advice. yahoo! has not been able to grow the business away from alibaba. they got a big stake in alibaba, that wasn't bad, but they haven't been able to monetize it. until then i do not think the stock with worthy of your attention, versus alphabet nee google, which sells at almost a market multiple now. best in breed, florence. thank you everyone for those great comments. it's about having the discipline to buy when everyone despises the market at that one moment and sell when everyone loves it. put yourself in the other person's head and opportunity could come knocking. the last time i spoke to alva biopharma, the company has seen

its share slide 40%. i've got the ceo. then i'm taking the opportunity to review the portfolio. of course your calls, rapid fire, in tonight's edition of the lightning round.

♪ light piano today i saw a giant. it had no arms, but it welcomed me. (crow cawing) it had no heart, but it was alive. (train wheels on tracks) it had no mouth, but it spoke to me. it said, "rocky mountaineer: all aboard amazing". it's gotten squarer. over the years. brighter. bigger.

it's gotten thinner. even curvier. but what's next? for all binge watchers. movie geeks. sports freaks. x1 from xfinity will change the way you experience tv. look at alder pharmaceuticals roar. it rallied three bucks, rocketing into the stratosphere. if people feel like it's finally safe to speculate in biotechs again, it might have more room to run given that the stock is still down 48% from the highs. of course if the bounce is ephemeral, then the stock could

repeal the entire gain. this company specializes in developing antibody therapies including treatment for inflammatory diseases like arthritis. while this is important, a biotech company with just one or two drugs in phase iii trials is a much more speculative stock. this is a highly speculative stock. it jackknifed up 11% today. not the kind of stock you want for your retirement fund. by the way, let me just say it, alder is a spec for younger players. it has a lot going for it. the huge decline in the stock in the last several months mean you can afford it now. randall schatzman is the ceo.

welcome back to "mad money." >> thank you, jim, good to be with you again. >> sir, i have to ask you, because i know our viewers will say, there any way you could do your job and look at the stock? it's something that is a very long term proposition. >> it's clearly been a rocky week on wall street. i would agree with you on that front. i think the thing for your viewers to understand is that the biopharma space has actually never been stronger. the fundamentals are sound. in 2015, it was actually its most productive year. about 45 new molecular entities were approved by the fda. the interest by big pharma is also at a high. big pharma is looking to this industry to provide that innovation for their own pipelines. >> let's talk about that, doctor. you have a migraine prevention drug.

you've got this handout that comes from this conference that is really unbelievable. rapid onset of 100% migraine prevention. this is for your ald 403. these are remarkable figures. migraine sufferers should be clamoring for this. >> in fact there is high interest in this. and i think this is really on the back of the success of the scientists at alder. they've been able to identify a therapeutic that neutralizes what we believe is the primary initiating factor for migraines and target it in a way that we can prevent migraines happening in these patients altogether. >> 36 million americans suffer from migraines. only 22.3 million migraine sufferers have been clinically diagnosed. how do you reach that population? how do you get the word out? given the data, i have to

believe that people are really suffering that maybe could have a real break here. >> yes, you're exactly right, jim. and i think the key here is really about reaching out through social media. today, almost every patient is on the lookout for new forms of therapy that can alleviate the suffering that they have. we're making the most of that in reaching out to those patients. >> let's talk about the competition. we've got some slides. it's clear from the slides, anybody can get this, it's really rather remarkable. you are well ahead of a bunch of companies, amgen, lily, teva. allergan came on and talked about its migraine formulation that it's bullish about. they'll be teaming up with pfizer. how do you compete against giant companies that say they have a better mousetrap here? >> first and foremost, again, i think the alder scientists have

discovered a therapeutic that we believe has best in class properties. and to be honest, in a word, we think alder can lead the way in terms of innovation, how we're viewing the best way to introduce this therapeutic to patients. and we can bring novelty to the table that we believe some of the bigger place are not able to do. >> you were able to raise some capital. when you go down like this, there's a lot of biotech companies that are so small now because the market is taking us down, we're going to get a call from a major pharmaceutical company and take out our upside by offering an attractive premium to people who just got in but it's disappointing if you take a long term view. >> i would agree with that. obviously there is high interest in this space, in treating the huge number of patients that are here. i think that for our investors, we've got some very key catalysts that are coming in 2016. and they should be looking out

for those. hopefully along the way that will bring some positive return for those investors. >> and rheumatoid arthritis going along well? >> going very well. i think we'll have some news on that front from that drug later this year as well. >> last question, when you see this different -- you look at the well-tolerated with no major side effects, the first thing i said was, is there ever a chance that the fda says, let's just let people have this thing, because the side effects, it shows well-tolerated, millions of people are suffering from it, let's just give it to them? >> well, in fact i think the fda has responded positively in that sense. about 4,000 patients have now been treated with agents that are targeting the biology that we're targeting across the four programs that are out there. they've shown a very promising safety profile. and in that respect, the fda recognizes that and is actually

working with each of the companies to expedite the development programs. in all honest, i do think we want to take them through a development program that's very rational so that what we deliver to patients has the exquisite safety profile we want it to have. >> when it was high, they all love it, when it's low, that's exactly when people should be buying it. dr. schatzman, thank you so much for coming on "mad money." >> thanks for having us back. >> best to buy these when they're hated, not when they're loved. alder biopharma, check the data out. "mad money" is back after the break.

>> announcer: lightning round is sponsored by td ameritrade. [ bell ringing ] >> it is time. it is time for the lightning round. you say the name of the stock. i don't know the calls or the name of the stock ahead of time. i tell you whether to buy or sell. when you hear this sound -- [ buzzer ] -- then the lightning round is over. are you ready, skee-daddy? time for the lightning round. bill from ohio. >> caller: hey, jim, thanks for

having me. i want to know if sunoco, buy or sell. >> it's part of a huge agglomeration that is occurring. sell, sell, sell, other parts of sector are better. use this lift to lighten up. paulette in louisiana. >> caller: hi, jim. booyah. >> booyah. >> caller: conocophillips. >> they are pledging to keep that dividend. this oil cannot go in the 20s. i believe they will come back up. they all need capital. addie in new jersey. addie. >> thanks for taking my call, jim. analie capital. >> too risky and they're value traps. fred in california.

>> caller: jim, how are you doing, man? with the takeover with target, cvs stock, buy, sell or hold? >> it's an incredibly well-run company. i prefer walgreen's. but walgreen's and cvs are good companies. gloria in south carolina. >> caller: hi there. just want to say you married really well, congratulations. >> thank you very much. >> caller: you look 15 years younger. acorn, buy, sell, or hold? >> that cleanse is helping too. the ginger smoothie. i don't know enough right now about how acorn is doing. i have to come back and do homework on them. isaac in new jersey. >> caller: hello? >> you're up, isaac. >> caller: how are you doing? it's isaac from new jersey. thank you very much for your

job. >> thank you. >> caller: i bought stock ardelyx. >> i'm checking the biotech bible i put together. i've got to study this. i'm not kidding, it's the biotech bible, i put it together with some people. so i cannot opine correctly on that one. let's go to nick in california. >> caller: booyah, jim, from the west coast. >> how are you? >> caller: lc lending club. >> i can't go down that road when i have the possibility of investing in j.p. morgan. that, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade.

l the time. sup jj, working hard? working 24/7 on mobile trader, rated #1 trading app on the app store. it lets you trade stocks, options, futures... even advanced orders. and it offers more charts than a lot of other competitors do on desktop. you work so late. i guess you don't see your family very much? i see them all the time. did you finish your derivatives pricing model, honey? td ameritrade.

cramerica. it's time for the first game of am i diversified in 2016. triple digit rallies, enough to make your head spin. this is when you can really lose a lot of money. i get it, you see the alder for

him today, this is the time to load up for the future. ensuring your diversification is the best way to keep your portfolio safe and secure. it will keep you from losing money. sometimes that's all you want. it's where you call or tweet me and i'll tell you if you're diversified enough and where you need to mix it up a little. let's start with a tweet. this one says, black rock, cardinal health, disney, harmon international, and eqix. i like black rock, it's incredibly well-run. cardinal health is a very good company. disney is in the entertainment business. eqix is the hal servers, a very

good business. armon is the entertainment audio company, kind of a real estate for servers. entertainment, healthcare, and finance. that is perfect. honestly, that is absolutely a perfect portfolio, not going to be able to be sunk by just one sector. cory in massachusetts. >> caller: thanks for having me on. so i got nike, fantastic earnings call, the last quarter they had. celgene, your favorite. i got berkshire hathaway, the b class. i've got google. i've got dextrecom. what are your thoughts? >> wow, this is tough. it's to have because i'm going to have to make a decision about which one of these has to go in the pharmaceuticals. you can't have both of them. it's very difficult because

dexcom and celgene are excellent companies. they are in basically the same business of healthcare. i'm going to say celgene because it's down so much. nike, obviously shoe apparel, the stock not doing well right now, i think that might be an opportunity to go down a couple. let's put in general electric, okay? let's put in ge. we're reading all those articles about the innovation company moving to boston, i think that's the right call. you need an industrial. that will take the place of dexcom. if you only had celgene or only had dexcom, i would not have made that change because dexcom is great. ben in florida. >> caller: my stocks are apple, disney, nike, at&t and bank of america. >> let's take a look at this.

okay. nike, i just went over that. bank of america, i have a lot of it for the travel trust. don't think it's going to run away to the upside but i do feel like this is the year. disney, under fire for cable and espn, i think it's fine. and then apple, after the close of analog devices, they did say things are quite weak. we're not into apple for the near term. in the near term we know that cellphones have peaked. we're in it for longer, better reasons. that's all right. tech and telco, apparel, banking, and entertainment. that works for me. good call. stick with cramer. or stop to find a bathroom? cialis for daily use is approved to treat both erectile dysfunction and the urinary symptoms of bph, like needing to go frequently, day or night. tell your doctor about all your medical conditions and medicines, and ask if your heart is healthy enough for sex.

do not take cialis if you take nitrates for chest pain, as it may cause an unsafe drop in blood pressure. do not drink alcohol in excess. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have any sudden decrease or loss in hearing or vision, or any symptoms of an allergic reaction, stop taking cialis and get medical help right away. ask your doctor about cialis and a $200 savings card

all right. two semiconductor companies, intel has too much inventory. that could color some of the action tomorrow. remember, technology was a leader today. it's hard to have a leader group go up again when intel and analog devices are saying things that frankly don't sound that hot to me. but that's an okay. remember, we're addressing things one check at a time. there's always a bull market somewhere and i promise to find it for you right here at "mad money." i'm jim cramer. i'll see you tomorrow! matic mus]

♪ matic mus] >> male narrator: tonight, on restaurant startup, a star will be born as two ambitious chefs fight for a shot at the spotlight. a culinary showman who's made himself the main attraction... >> the interactive culinary experience where the chef's cook in front of you. >> narrator: a michelin-starred maestro, staking his comeback on a single ingredient... >> inside this briefcase, i hold the key to making all of us millions of dollars. >> narrator: with hundreds of thousands of dollars on the line, will one of them earn an investment from joe or tim? joe bastianich owns a portfolio of 30 acclaimed restaurants along with eataly, a high-end italian market. tim love is a celebrity chef with eight award-winning restaurants and a retail empire.